CompletedPhase 2

Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

France84 participantsStarted 2006-07

Plain-language summary

The study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress Syndrome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients suffering from persistent ARDS as defined by the American and European Consensus Conference on ARDS, 1994 Exclusion Criteria: * ARDS secondary to traumatism * Pulmonary emphysema on pulmonary fibrosis * Lung pneumocystosis * Bronchopleural fistula * Systemic corticosteroid treatment for more than 2 weeks before inclusion * Severe organ disease excepted renal

What they're measuring

Static compliance relative change from pre-treatment to last on treatment

Trial details

NCT IDNCT00455767

SponsorDebiopharm International SA

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-09

View on ClinicalTrials.gov More Fibrosis trials